1 | Chapter 1: Introduction | 14 |
1.1 | Executive Summary | 14 |
1.2 | Topics Covered | 15 |
1.3 | Historical Revenue & Forecast Segmentation | 16 |
1.4 | Key Questions Answered | 18 |
1.5 | Key Findings | 19 |
1.6 | Methodology | 20 |
1.7 | Target Audience | 21 |
1.8 | Companies & Organizations Mentioned | 22 |
2 | Chapter 2: An Overview of Generic Drugs | 26 |
2.1 | What is a Generic Drug? | 26 |
2.2 | Reserve Engineering: How Are Generics Conceived? | 26 |
2.3 | The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs? | 27 |
2.3.1 | What Defines Bioequivalence? | 27 |
2.3.2 | Acceptable Bioequivalence Ranges | 27 |
2.4 | The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts? | 28 |
2.5 | Economics: Price Comparison | 28 |
2.6 | Brand Classification: Pure vs. Branded Generics | 29 |
2.6.1 | Pure (Non-branded) Generics | 29 |
2.6.2 | Branded Generics | 29 |
2.6.3 | Super Generics | 30 |
2.7 | Market Growth Drivers | 31 |
2.7.1 | Cost Effectiveness and Affordability | 31 |
2.7.2 | Low Insurance Premiums | 31 |
2.7.3 | Patent Expiry of Innovator Drugs | 31 |
2.7.4 | Political & Regulatory Support | 32 |
2.7.5 | Global Proliferation & Increasing Demand | 32 |
2.8 | Market Barriers | 33 |
2.8.1 | Patent Linkage: Delaying Product Launch | 33 |
2.8.2 | Complex Product Portfolios | 33 |
2.8.3 | Quality Control Issues | 33 |
2.8.4 | Intense Competitive Landscape | 34 |
2.8.5 | Resistance from Big Pharma Players | 34 |
3 | Chapter 3: Regulatory Landscape | 35 |
3.1 | Regional Outlook | 35 |
3.1.1 | Asia Pacific | 35 |
3.1.2 | Europe | 37 |
3.1.3 | Middle East & Africa | 38 |
3.1.4 | Latin & Central America | 39 |
3.1.5 | North America | 40 |
3.2 | International Initiatives | 41 |
3.2.1 | WHO Guidelines | 41 |
3.2.2 | IGDRP (International Generic Drug Regulators Pilot) | 41 |
3.2.3 | EMA (European Medicines Agency): Extending Collaboration beyond the EU | 42 |
4 | Chapter 4: Drug Class Availability & Leading Therapies | 43 |
4.1 | Drug Class Availability | 43 |
4.1.1 | Antibiotics | 43 |
4.1.2 | Cardiovascular & Hypertension | 43 |
4.1.3 | CNS (Central Nervous System) | 44 |
4.1.4 | Dermatology | 44 |
4.1.5 | Diabetes | 45 |
4.1.6 | Gastrointestinal | 45 |
4.1.7 | Hormonal Drugs | 46 |
4.1.8 | Onocology | 46 |
4.1.9 | Pain Relief | 46 |
4.1.10 | Respiratory | 47 |
4.1.11 | Rheumatology | 47 |
4.1.12 | Other Categories | 47 |
4.2 | Leading Generic Drugs | 48 |
4.2.1 | Acetaminophen (Paracetamol) | 48 |
4.2.2 | Alprazolam | 48 |
4.2.3 | Amlodipine | 48 |
4.2.4 | Amoxicillin | 48 |
4.2.5 | Asprin (Acetylsalicylic Acid) | 49 |
4.2.6 | Atenolol | 49 |
4.2.7 | Atorvastatin | 49 |
4.2.8 | Azithromycin | 49 |
4.2.9 | Bendroflumethiazide | 50 |
4.2.10 | Betamethasone Dipropionate | 50 |
4.2.11 | Candesartan | 50 |
4.2.12 | Clavulanic Acid | 50 |
4.2.13 | Clopidogrel | 51 |
4.2.14 | Dexamfetamine | 51 |
4.2.15 | Diclofenac | 51 |
4.2.16 | Doxycycline | 51 |
4.2.17 | Enalapril | 51 |
4.2.18 | Enoxaparin Sodium | 52 |
4.2.19 | Esomeprazole | 52 |
4.2.20 | Fentanyl | 52 |
4.2.21 | Fenofibrate | 52 |
4.2.22 | HCTZ (Hydrochlorothiazide) | 52 |
4.2.23 | Ibuprofen | 53 |
4.2.24 | Lansoprazole | 53 |
4.2.25 | Levothyroxine Sodium | 53 |
4.2.26 | Lisinopril | 53 |
4.2.27 | Losartan | 54 |
4.2.28 | Metformin | 54 |
4.2.29 | Methylphenidate | 54 |
4.2.30 | Methotrexate | 54 |
4.2.31 | Metoprolol | 55 |
4.2.32 | Omeprazole | 55 |
4.2.33 | Pantoprazole | 55 |
4.2.34 | Perindopril | 55 |
4.2.35 | Ramipril | 56 |
4.2.36 | Rosuvastatin | 56 |
4.2.37 | Salbutamol (Albuterol) | 56 |
4.2.38 | Simvastatin | 56 |
4.2.39 | Valsartan | 57 |
4.2.40 | Venlafaxine | 57 |
4.2.41 | Others | 57 |
5 | Chapter 5: Generic Drugs Industry Roadmap & Value Chain | 60 |
5.1 | Industry Roadmap | 60 |
5.1.1 | 2015 – 2020: Overtaking Innovator Drugs | 60 |
5.1.2 | 2020 – 2025: The Era of Generic Biologics | 61 |
5.1.3 | 2025 – 2030 & Beyond: Evolving Regulatory Landscape | 61 |
5.2 | Value Chain | 62 |
5.2.1 | API Manufacturers & Enabling Technology Providers | 62 |
5.2.1 | Generic Drug Manufacturers | 63 |
5.2.2 | Innovator Pharmaceutical Companies | 63 |
5.2.3 | Regional Distributors | 64 |
5.2.4 | Healthcare Providers, Pharmacies & Drug Stores | 64 |
6 | Chapter 6: Key Market Players | 65 |
6.1 | Abbott Laboratories | 65 |
6.2 | AbbVie | 66 |
6.3 | ACETO Corporation | 67 |
6.4 | Acino Holding | 68 |
6.5 | Actavis | 69 |
6.6 | Actelion | 71 |
6.7 | Adcock Ingram | 72 |
6.8 | Ajinomoto | 73 |
6.9 | Akron | 74 |
6.10 | Alexion Pharmaceuticals | 75 |
6.11 | Alfa Wasserman | 76 |
6.12 | Amgen | 77 |
6.13 | AMRI (Albany Molecular Research, Inc.) | 78 |
6.14 | Amneal Pharmaceuticals | 79 |
6.15 | Apotex | 80 |
6.16 | ASKA Pharmaceutical Company | 81 |
6.17 | Aspen Holdings | 82 |
6.18 | Astellas Pharma | 83 |
6.19 | AstraZeneca | 84 |
6.20 | Aurobindo Pharma | 85 |
6.21 | Baxter BioScience | 86 |
6.22 | Bayer AG | 87 |
6.23 | BD (Becton, Dickinson and Company) | 88 |
6.24 | Biogen Idec | 89 |
6.25 | Biocon | 90 |
6.26 | Boehringer Ingelheim | 91 |
6.27 | BMS (Bristol-Myers Squibb) | 92 |
6.28 | Cadila Healthcare (Zydus Cadila) | 93 |
6.29 | Cadila Pharmaceuticals | 94 |
6.30 | Celgene Corporation | 95 |
6.31 | Chiesi Farmaceutici | 96 |
6.32 | Chugai Pharmaceutical Company | 97 |
6.33 | Claris Lifesciences | 98 |
6.34 | Cipla | 99 |
6.35 | Coherus BioSciences | 100 |
6.36 | Consort Medical | 101 |
6.37 | Daiichi Sankyo | 102 |
6.38 | Dong-A Pharmaceutical | 103 |
6.39 | Dr. Reddy's Laboratories | 104 |
6.40 | Eisai Company | 105 |
6.41 | Eli Lilly and Company | 106 |
6.42 | Endo International | 107 |
6.43 | ESTEVE Group | 108 |
6.44 | Eurofarma Laboratorios | 109 |
6.45 | Ferring Pharmaceuticals | 110 |
6.46 | Fresenius Kabi | 111 |
6.47 | Fujifilm Pharma Company | 112 |
6.48 | Fuji Pharma Company | 113 |
6.49 | Galderma | 114 |
6.50 | Galenika | 115 |
6.51 | Gedeon Richter | 116 |
6.52 | Genepharm | 117 |
6.53 | Gilead Sciences | 118 |
6.54 | Glenmark Pharmaceuticals | 119 |
6.55 | Grifols | 120 |
6.56 | Gruenenthal Group | 121 |
6.57 | GSK (GlaxoSmithKline) | 122 |
6.58 | Hanmi Pharmaceutical Company | 123 |
6.59 | Hetero Drugs | 124 |
6.60 | Hikma Pharmaceuticals | 125 |
6.61 | Hospira | 126 |
6.62 | Impax Laboratories | 127 |
6.63 | Ipsen | 128 |
6.64 | JT (Japan Tobacco) | 129 |
6.65 | Jazz Pharmaceuticals | 130 |
6.66 | Johnson & Johnson | 131 |
6.67 | Kaken Pharmaceutical Company | 132 |
6.68 | Kaneka Corporation | 133 |
6.69 | Kowa Company | 134 |
6.70 | Kremers Urban Pharmaceuticals | 135 |
6.71 | Krka (Krka, d. d.) | 136 |
6.72 | Kyowa Hakko Kirin Company | 137 |
6.73 | Laboratorios Roemmers | 138 |
6.74 | Leo Pharma | 139 |
6.75 | Les Laboratoires Servier | 140 |
6.76 | Lundbeck (H. Lundbeck A/S) | 141 |
6.77 | Lupin | 142 |
6.78 | Mallinckrodt | 143 |
6.79 | Maruho Company | 144 |
6.80 | Meda | 145 |
6.81 | Meiji Holdings | 146 |
6.82 | Menarini Group | 147 |
6.83 | Merck and Co. | 148 |
6.84 | Merck KGaA | 150 |
6.85 | Merz Pharma | 151 |
6.86 | Mitsubishi Tanabe Pharma | 152 |
6.87 | Mitsui & Company | 153 |
6.88 | Mylan | 154 |
6.89 | Natco Pharma | 155 |
6.90 | Nichi-Iko Pharmaceutical Company | 156 |
6.91 | Nippon Kayaku | 157 |
6.92 | Nippon Shinyaku | 158 |
6.93 | Nipro Pharma Corporation | 159 |
6.94 | Novo Nordisk | 160 |
6.95 | Ono Pharmaceutical Company | 161 |
6.96 | Orion Corporation | 162 |
6.97 | Otsuka Holdings Company | 163 |
6.98 | Par Pharmaceutical Companies | 164 |
6.99 | Perrigo Company | 165 |
6.100 | Pfizer | 166 |
6.101 | Pharmstandard | 167 |
6.102 | Pierre Fabre (Laboratoires Pierre Fabre) | 168 |
6.103 | Piramal Enterprises | 169 |
6.104 | Pliva (Pliva d.d.) | 170 |
6.105 | Prasco Laboratories | 171 |
6.106 | Purdue Pharma | 172 |
6.107 | Ranbaxy Laboratories | 173 |
6.108 | Recordati | 174 |
6.109 | Regeneron Pharmaceuticals | 175 |
6.110 | Roche Holding (F. Hoffmann-La Roche) | 176 |
6.111 | Salix Pharmaceuticals | 177 |
6.112 | Samsung Group | 178 |
6.113 | Sandoz International (Novartis International) | 179 |
6.114 | Sanofi | 180 |
6.115 | Santen Pharmaceutical Company | 181 |
6.116 | Sawai Pharmaceutical Company | 182 |
6.117 | Seikagaku Corporation | 183 |
6.118 | Sequent Scientific | 184 |
6.119 | Shionogi & Company | 185 |
6.120 | Shire | 186 |
6.121 | Sigma-Tau | 187 |
6.122 | STADA Arzneimittel | 188 |
6.123 | Strides Arcolab | 189 |
6.124 | Sumitomo Dainippon Pharma Company | 190 |
6.125 | Sun Pharmaceutical Industries | 191 |
6.126 | Taisho Pharmaceutical Holdings Company | 192 |
6.127 | Takeda Pharmaceutical Company | 193 |
6.128 | Teijin | 194 |
6.129 | Teva Pharmaceutical Industries | 195 |
6.130 | The Medicines Company | 196 |
6.131 | Torrent Pharmaceuticals | 197 |
6.132 | Towa Pharmaceutical Company | 198 |
6.133 | UCB | 199 |
6.134 | United Therapeutics Corporation | 200 |
6.135 | Valeant Pharmaceuticals International | 201 |
6.136 | Vertex Pharmaceuticals | 202 |
6.137 | Wockhardt | 203 |
7 | Chapter 7: Market Analysis & Forecasts | 204 |
7.1 | Global Outlook of Generic Drugs | 204 |
7.2 | Segmentation by Brand Classification | 205 |
7.2.1 | Pure (Non-branded) Generics | 205 |
7.2.2 | Branded Generics | 206 |
7.2.3 | Super Generics | 206 |
7.3 | Segmentation by Therapeutic Area | 207 |
7.3.1 | Antibiotics | 207 |
7.3.2 | Cardiovascular & Hypertension | 208 |
7.3.3 | CNS | 208 |
7.3.4 | Dermatology | 209 |
7.3.5 | Diabetes | 209 |
7.3.6 | Gastrointestinal | 210 |
7.3.7 | Hormonal Drugs | 210 |
7.3.8 | Oncology | 211 |
7.3.9 | Pain Relief | 211 |
7.3.10 | Respiratory | 212 |
7.3.11 | Rheumatology | 212 |
7.3.12 | Others | 213 |
7.4 | Segmentation by Region | 214 |
7.4.1 | Asia Pacific | 214 |
7.4.2 | Europe | 215 |
7.4.3 | Middle East & Africa | 215 |
7.4.4 | Latin & Central America | 216 |
7.4.5 | North America | 216 |
7.5 | Top Country Markets | 217 |
7.5.1 | Brazil | 217 |
7.5.2 | Canada | 218 |
7.5.3 | China | 219 |
7.5.4 | Egypt | 220 |
7.5.5 | France | 221 |
7.5.6 | Germany | 222 |
7.5.7 | Greece | 223 |
7.5.8 | India | 224 |
7.5.9 | Israel | 225 |
7.5.10 | Italy | 226 |
7.5.11 | Japan | 227 |
7.5.12 | Mexico | 228 |
7.5.13 | Netherlands | 229 |
7.5.14 | Poland | 230 |
7.5.15 | Portugal | 231 |
7.5.16 | Russia | 232 |
7.5.17 | Saudi Arabia | 233 |
7.5.18 | South Africa | 234 |
7.5.19 | South Korea | 235 |
7.5.20 | Spain | 236 |
7.5.21 | Switzerland | 237 |
7.5.22 | Taiwan | 238 |
7.5.23 | Turkey | 239 |
7.5.24 | UK | 240 |
7.5.25 | USA | 241 |
8 | Chapter 8: Conclusion & Strategic Recommendations | 242 |
8.1 | Why is the Market Poised to Grow? | 242 |
8.2 | Are Generic Drugs Becoming Expensive? | 242 |
8.3 | Competitive Industry Landscape: Acquisitions, Alliances & Consolidation | 243 |
8.4 | High Profile Recalls: What is the Impact on the Market? | 244 |
8.5 | Lower-Cost Countries: Increasing R&D and Manufacturing Investments | 244 |
8.6 | Geographic Outlook: Which Countries Offer the Highest Growth Potential? | 245 |
8.7 | Prospects of Biosimilars | 246 |
8.7.1 | How Big is the Biosimilars Opportunity? | 246 |
8.7.2 | Regulatory Status | 247 |
8.8 | Strategic Recommendations | 248 |
8.8.1 | Generic Drug Manufacturers | 248 |
8.8.2 | Innovators | 248 |
List of Figures | ||
Figure 1: Price Comparison between Generic and Innovator Drugs | 29 | |
Figure 2: Generic Drugs Revenue Share by Brand Classification | 30 | |
Figure 3: Generic Drugs Industry Roadmap | 60 | |
Figure 4: Generic Drugs Value Chain | 62 | |
Figure 5: Global Generic Drugs Revenue ($ Million): 2015 - 2030 | 204 | |
Figure 6: Global Generic Drugs Revenue by Brand Classification ($ Million): 2015 - 2030 | 205 | |
Figure 7: Pure (Non-branded) Generic Drugs Revenue ($ Million): 2015 - 2030 | 205 | |
Figure 8: Branded Generic Drugs Revenue ($ Million): 2015 - 2030 | 206 | |
Figure 9: Super Generic Drugs Revenue ($ Million): 2015 - 2030 | 206 | |
Figure 10: Global Generic Drugs Revenue by Therapeutic Area ($ Million): 2015 - 2030 | 207 | |
Figure 11: Generic Antibiotic Drugs Revenue ($ Million): 2015 - 2030 | 207 | |
Figure 12: Generic Cardiovascular & Hypertension Drugs Revenue ($ Million): 2015 - 2030 | 208 | |
Figure 13: Generic CNS Drugs Revenue ($ Million): 2015 - 2030 | 208 | |
Figure 14: Generic Dermatology Drugs Revenue ($ Million): 2015 - 2030 | 209 | |
Figure 15: Generic Diabetes Drugs Revenue ($ Million): 2015 - 2030 | 209 | |
Figure 16: Generic Diabetes Drugs Revenue ($ Million): 2015 - 2030 | 210 | |
Figure 17: Generic Hormonal Drugs Revenue ($ Million): 2015 - 2030 | 210 | |
Figure 18: Generic Oncology Drugs Revenue ($ Million): 2015 - 2030 | 211 | |
Figure 19: Generic Pain Relief Drugs Revenue ($ Million): 2015 - 2030 | 211 | |
Figure 20: Generic Respiratory Drugs Revenue ($ Million): 2015 - 2030 | 212 | |
Figure 21: Generic Rheumatology Drugs Revenue ($ Million): 2015 - 2030 | 212 | |
Figure 22: Other Generic Drugs Revenue ($ Million): 2015 - 2030 | 213 | |
Figure 23: Global Generic Drugs Revenue by Region ($ Million): 2015 - 2030 | 214 | |
Figure 24: Asia Pacific Generic Drugs Revenue ($ Million): 2015 - 2030 | 214 | |
Figure 25: Europe Generic Drugs Revenue ($ Million): 2015 - 2030 | 215 | |
Figure 26: Middle East & Africa Generic Drugs Revenue ($ Million): 2015 - 2030 | 215 | |
Figure 27: Latin & Central America Generic Drugs Revenue ($ Million): 2015 - 2030 | 216 | |
Figure 28: North America Generic Drugs Revenue ($ Million): 2015 - 2030 | 216 | |
Figure 29: Brazil Generic Drugs Revenue ($ Million): 2015 - 2030 | 217 | |
Figure 30: Canada Generic Drugs Revenue ($ Million): 2015 - 2030 | 218 | |
Figure 31: China Generic Drugs Revenue ($ Million): 2015 - 2030 | 219 | |
Figure 32: Egypt Generic Drugs Revenue ($ Million): 2015 - 2030 | 220 | |
Figure 33: France Generic Drugs Revenue ($ Million): 2015 - 2030 | 221 | |
Figure 34: Germany Generic Drugs Revenue ($ Million): 2015 - 2030 | 222 | |
Figure 35: Greece Generic Drugs Revenue ($ Million): 2015 - 2030 | 223 | |
Figure 36: India Generic Drugs Revenue ($ Million): 2015 - 2030 | 224 | |
Figure 37: Israel Generic Drugs Revenue ($ Million): 2015 - 2030 | 225 | |
Figure 38: Italy Generic Drugs Revenue ($ Million): 2015 - 2030 | 226 | |
Figure 39: Japan Generic Drugs Revenue ($ Million): 2015 - 2030 | 227 | |
Figure 40: Mexico Generic Drugs Revenue ($ Million): 2015 - 2030 | 228 | |
Figure 41: Netherlands Generic Drugs Revenue ($ Million): 2015 - 2030 | 229 | |
Figure 42: Poland Generic Drugs Revenue ($ Million): 2015 - 2030 | 230 | |
Figure 43: Portugal Generic Drugs Revenue ($ Million): 2015 - 2030 | 231 | |
Figure 44: Russia Generic Drugs Revenue ($ Million): 2015 - 2030 | 232 | |
Figure 45: Saudi Arabia Generic Drugs Revenue ($ Million): 2015 - 2030 | 233 | |
Figure 46: South Africa Generic Drugs Revenue ($ Million): 2015 - 2030 | 234 | |
Figure 47: South Korea Generic Drugs Revenue ($ Million): 2015 - 2030 | 235 | |
Figure 48: Spain Generic Drugs Revenue ($ Million): 2015 - 2030 | 236 | |
Figure 49: India Generic Drugs Revenue ($ Million): 2015 - 2030 | 237 | |
Figure 50: Taiwan Generic Drugs Revenue ($ Million): 2015 - 2030 | 238 | |
Figure 51: Turkey Generic Drugs Revenue ($ Million): 2015 - 2030 | 239 | |
Figure 52: UK Generic Drugs Revenue ($ Million): 2015 - 2030 | 240 | |
Figure 53: USA Generic Drugs Revenue ($ Million): 2015 - 2030 | 241 | |
Figure 54: Global Biosimilar Drugs Revenue by Approval Category ($ Million): 2015 - 2030 | 246 |
NA
Abbott Laboratories |
AbbVie |
ACETO Corporation |
Acino Holding |
Actavis |
Actelion |
Adcock Ingram |
Aesica Pharmaceuticals |
Ajinomoto |
Akron |
Alexion Pharmaceuticals |
Alfa Wasserman |
Allergan |
Almirall |
AMA (African Medicines Regulatory Agency) |
Amgen |
Amneal Pharmaceuticals |
AMRI (Albany Molecular Research, Inc.) |
ApoPharma |
Apotex |
Arch Pharmalabs |
ASKA Pharmaceutical Company |
Aspen Holdings |
Astellas Pharma |
AstraZeneca |
Aurobindo Pharma |
Auxilium Pharmaceuticals |
Baxter BioScience |
Baxter International |
Bayer AG |
BD (Becton, Dickinson and Company) |
BD Rx |
Berlin Chemie |
Biocon |
Biogaran |
Biogen Idec |
Biogen Laboratorios |
BMS (Bristol-Myers Squibb) |
Boehringer Ingelheim |
Boots UK |
BPI (Breckenridge Pharmaceutical Inc.) |
Breckenridge Pharmaceutical |
Cadila Healthcare (Zydus Cadila) |
Cadila Pharmaceuticals |
CBER (Centre for Biologics Evaluation and Research) |
CDER (Centre for Drug Evaluation and Research) |
CDSCO (Central Drug Standards and Control Organization, India) |
Cedarburg Pharmaceuticals |
Celgene Corporation |
Celltrion Group |
CFDA (China Food and Drug Administration) |
Chiesi Farmaceutici |
Chugai Pharmaceutical Company |
Cipla |
Claris Injectables |
Claris Lifesciences |
Claris Otsuka |
Coherus BioSciences |
Consort Medical |
Covidien |
Cubist Pharmaceuticals |
Cypress Pharmaceutical |
Daiichi Sankyo |
Daiichi Sankyo Espha |
Dong-A Pharmaceutical |
Dr. Reddy's Laboratories |
Dusa Pharmaceuticals |
EGA (European Generic Medicines Association) |
Egis Pharmaceuticals |
Eisai Company |
Eli Lilly and Company |
Elmed Eisai Company |
EMA (European Medicines Agency) |
Endo International |
Endo Pharmaceuticals |
ESTEVE Farma |
ESTEVE Group |
Eurofarma Laboratorios |
FDA (Food and Drug Administration) |
Ferring Pharmaceuticals |
Forest Laboratories |
Fresenius Kabi |
Fuji Pharma Company |
Fujifilm Corporation |
Fujifilm Holdings Corporation |
Fujifilm Pharma Company |
Galderma |
Galenika |
Gedeon Richter |
Gedeon Richter PregLem |
Genepharm |
GGL (Glenmark Generics Limited) |
Gilead Sciences |
Glenmark Pharmaceuticals |
Global Pharmaceuticals |
Globalpharma |
Grifols |
Gruenenthal Group |
GSK (GlaxoSmithKline) |
Guangdong BeiKang Pharmaceutical Company |
Hanmi Pharmaceutical Company |
Health Canada |
Hetero Drugs |
Hikma Pharmaceuticals |
Hi-Tech Pharmacal |
Hospira |
Impax Laboratories |
Impax Pharmaceuticals |
Ipsen |
Janssen Pharmaceutica |
Jazz Pharmaceuticals |
JHP Group Holdings |
JHP Pharmaceuticals |
Johnson & Johnson |
JT (Japan Tobacco) |
Kaken Pharmaceutical Company |
Kaneka Corporation |
Kowa Company |
Kowa Health Care America |
Kowa Pharmaceuticals America |
Kowa Research Institute |
Kremers Urban Pharmaceuticals |
Krka (Krka, d. d.) |
Kyowa Hakko Kirin Company |
Kyowa Pharmaceutical Industry Company |
Laboratorios Roemmers |
Leo Pharma |
Les Laboratoires Servier |
Lil Therapeutics |
Lundbeck (H. Lundbeck A/S) |
Lupin |
Mallinckrodt |
Maruho Company |
Matrix Laboratories |
Meda |
Medley Farma |
Meiji Holdings |
Meiji Seika Pharma Company |
Menarini Group |
Merck and Co. |
Merck KGaA |
Merck Serono |
Merz Pharma |
Ministry of Health, Labour and Welfare (Japan) |
Mitsubishi Chemical Holdings Corporation |
Mitsubishi Tanabe Pharma |
Mitsui & Company |
Mitsui Group |
MN (Mustafa Nevzat) Pharma |
Mylan |
Natco Pharma |
Nichi-Iko Pharmaceutical Company |
Nippon Kayaku |
Nippon Shinyaku |
Nipro Pharma Corporation |
Novartis International |
Novo Nordisk |
OLIC (Thailand) |
Ono Pharmaceutical Company |
Orion Corporation |
Osaka Synthetic Chemical Laboratories |
Otsuka Holdings Company |
Otsuka Pharmaceutical Company |
Paladin Labs |
Par Pharmaceutical Companies |
Pensa Dose |
Pensa Pharm |
Perrigo Company |
Pfizer |
Pharma Dynamics |
Pharmstandard |
Pierre Fabre (Laboratoires Pierre Fabre) |
Piramal Enterprises |
Piramal Group |
Pliva (Pliva d.d.) |
Prasco Laboratories |
PregLem |
Purdue Pharma |
Qualitest and Vintage Pharmaceuticals |
Ranbaxy Laboratories |
Recordati |
Regeneron Pharmaceuticals |
Rising Pharmaceuticals |
Roche Holding (F. Hoffmann-La Roche) |
Roxane Laboratories |
Salix Pharmaceuticals |
Samsung Bioepis |
Samsung BioLogics |
Samsung Group |
Sandoz International |
Sanofi |
Sanofi-Aventis Nichi-Iko K.K. |
Santen Pharmaceutical Company |
Sawai Pharmaceutical Company |
Seikagaku Corporation |
Sequent Scientific |
Servier Group |
Shionogi & Company |
Shire |
Sigma-Tau |
Somar (Grupo Farmaceutico Somar) |
STADA Arzneimittel |
Strativa Pharmaceuticals |
Strides Arcolab |
Sumitomo Dainippon Pharma Company |
Sun Pharmaceutical Industries |
Supera Farma Laboratorios |
Taisho Pharmaceutical Company |
Taisho Pharmaceutical Holdings Company |
Taisho Pharmaceutical Industries |
Taiyo Pharmaceutical Industry Company |
Takeda Pharmaceutical Company |
Tanabe Seiyaku Hanbai Company |
Taro Pharmaceutical Industries |
Teijin |
Teijin Pharma |
Teva Pharmaceutical Industries |
Teva-Kowa Pharma Company |
The Medicines Company |
Torrent Group |
Torrent Pharmaceuticals |
Towa Pharmaceutical Company |
UCB |
United Therapeutics Corporation |
Valeant Pharmaceuticals International |
Ventana Medical Systems |
Vertex Pharmaceuticals |
Warner-Chilcott |
West-Ward Pharmaceuticals |
WHO (World Health Organization) |
Wockhardt |
Zentiva |
*If Applicable.